Immunopharmacological potential of selective phosphodiesterase inhibition.: I.: Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-α) biosynthesis in alveolar epithelial cells

被引:85
作者
Haddad, JJ [1 ]
Land, SC
Tarnow-Mordi, WO
Zembala, M
Kowalczyk, D
Lauterbach, R
机构
[1] Univ Calif San Francisco, Med Ctr, Dept Anesthesia & Perioperat Care, Neurosci Res Lab, San Francisco, CA 94143 USA
[2] Univ Dundee, Ninewells Hosp & Med Sch, Fac Med,Oxygen Signaling Grp, Tayside Inst Child Hlth,Ctr Res Human Dev, Dundee DD1 9SY, Scotland
[3] Univ Sydney, New Childrens Hosp Neonatal Serv, Sydney, NSW 2006, Australia
[4] Univ Sydney, Westmead Hosp, Dept Neonatal Med, Sydney, NSW 2006, Australia
[5] Jagiellonian Univ, Coll Med, Dept Clin Immunol, Krakow, Poland
[6] Jagiellonian Univ, Coll Med, Dept Microbiol & Neonatol, Krakow, Poland
关键词
D O I
10.1124/jpet.300.2.559
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In an attempt to elaborate in vitro on a therapeutic strategy that counteracts an inflammatory signal, we previously reported a novel immunopharmacological potential of glutathione, an antioxidant thiol, in regulating inflammatory cytokines. In the present study, we investigated the hypothesis that selective regulation of phosphodiesterases (PDEs), a family of enzymes that controls intracellular cAMP/cGMP degradation, differentially regulates proinflammatory cytokines. Selective PDE1 inhibition (8-methoxymethyl-3-isobutyl-1-methylxanthine) blockaded lipopolysaccharide-endotoxin (LPS)-mediated biosynthesis of interleukin (IL)-6, but this pathway had no inhibitory effect on tumor necrosis factor-alpha (TNF-alpha). Furthermore, inhibition of PDE3 (amrinone) abolished the effect of LPS on IL-6, but attenuated TNF-alpha production. Reversible competitive inhibition of PDE4 (rolipram) exhibited a potent inhibitory effect on IL-6 and a dual, biphasic (excitatory/inhibitory) effect on TNF-alpha secretion. Blockading PDE5 (4-{[3',4'-(methylenedioxy)benzyl] amino}-6-methoxyquinazoline) showed a high potency in reducing IL-6 production, but in a manner similar to the inhibition of PDE4, exhibited a biphasic effect on TNF-alpha biosynthesis. Simultaneous inhibition of PDE5, 6, and 9 (zaprinast), purported to specifically elevate intracellular cGMP, reduced, in a dose-independent manner, IL-6 and TNF-alpha biosynthesis. Finally, nonselective inhibition of FIDE by pentoxifylline suppressed LPS-mediated secretion of IL-6 and TNF-alpha. The involvement of specific PDE isoenzymes in differentially regulating LPS-mediated inflammatory cytokine biosynthesis indicates a novel approach to unravel the potential therapeutic targets that these isozymes constitute during the progression of inflammation within the respiratory epithelium.
引用
收藏
页码:559 / 566
页数:8
相关论文
共 81 条
[21]   Effects of the phosphodiesterase 4 inhibitor RPR 73401 in a model of immunological inflammation [J].
Ehinger, AM ;
Gorr, G ;
Hoppmann, J ;
Telser, E ;
Ehinger, B ;
Kietzmann, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 392 (1-2) :93-99
[22]  
Ekholm D, 1997, J IMMUNOL, V159, P1520
[23]   OVEREXPRESSION OF TRANSFORMING GROWTH FACTOR-ALPHA IN PSORIATIC EPIDERMIS [J].
ELDER, JT ;
FISHER, GJ ;
LINDQUIST, PB ;
BENNETT, GL ;
PITTELKOW, MR ;
COFFEY, RJ ;
ELLINGSWORTH, L ;
DERYNCK, R ;
VOORHEES, JJ .
SCIENCE, 1989, 243 (4892) :811-814
[24]   Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation [J].
Essayan, DM .
BIOCHEMICAL PHARMACOLOGY, 1999, 57 (09) :965-973
[25]   Anti-TNFα therapy of rheumatoid arthritis:: what have we learned? [J].
Feldmann, M ;
Maini, RN .
ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :163-196
[26]  
Freeman B A, 1993, Res Rep Health Eff Inst, P1
[27]   A novel dual regulator of tumor necrosis factor-α and interleukin-10 protects mice from endotoxin-induced shock [J].
Fukuda, T ;
Sumichika, H ;
Murata, M ;
Hanano, T ;
Adachi, K ;
Hisadome, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 391 (03) :317-320
[28]   Organization and regulation of mitogen-activated protein kinase signaling pathways [J].
Garrington, TP ;
Johnson, GL .
CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) :211-218
[29]  
Gómez-Cambronero L, 2000, J PHARMACOL EXP THER, V293, P670
[30]  
Griswold DE, 1998, J PHARMACOL EXP THER, V287, P705